3 completed, 1 active not recruiting, 1 terminated, 1 unknown. 6 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Pure Autonomic Failure: new trials by email Literature Review of Pure Autonomic Failure trials Research Report on Pure Autonomic Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lu AF82422 in Participants With Multiple System Atrophy Lu AF82422, Placebo - Multiple System Atrophy | Phase 2 | Active not recruiting | H. Lundbeck A/S | 64 | 2021-11-16 | 2026-04-13 |
| Automated Abdominal Binder for Orthostatic Hypotension automated abdominal binder, Sham binder, Placebo - Orthostatic Hypotension, Autonomic Failure | Phase 1 / Phase 2 | Completed | Vanderbilt University Medical Center | 28 | 2018-03-01 | 2026-05-05 |
| TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) TD-9855, Placebo - Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension | Phase 2 | Completed | Theravance Biopharma | 34 | 2017-09-09 | 2022-09-26 |
| Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy Double blinded IVIg, Double blinded Placebo, Single Blinded IVIg - Autoimmune Autonomic Ganglionopathy (AAG) | Phase 2 / Phase 3 | Completed | Beth Israel Deaconess Medical Center | 6 | 2012-02-01 | 2017-07-02 |
| Fipamezole in Neurogenic Orthostatic Hypotension Placebo, Fipamezole - Symptomatic Neurogenic Orthostatic Hypotension (NOH), Parkinson's Disease | Phase 2 | Unknown | Juvantia Pharma Ltd | 24 | 2008-09-01 | 2008-10-01 |
| Mechanisms of Hypoglycemia Associated Autonomic Failure naloxone, fructose, exercise - Diabetes Mellitus, Hypoglycemia | Phase 2 | Terminated | Albert Einstein College of Medicine | 39 | 2008-03-01 | 2026-05-19 |
Hypotension, Orthostatic (4) · Multiple System Atrophy (4) · Parkinson Disease (2) · Autonomic Nervous System Diseases (1) · Diabetes Mellitus (1) · Hypoglycemia (1) · Multiple system atrophy (MSA) with orthostatic hypotension (1) · Neurodegenerative Diseases (1) · Olivopontocerebellar Atrophies (1) · Shy-Drager Syndrome (1) · Striatonigral Degeneration (1)
Nervous System Diseases (6) · Primary Dysautonomias (6) · Autonomic Nervous System Diseases (5) · Basal Ganglia Diseases (4) · Brain Diseases (4) · Cardiovascular Diseases (4) · Central Nervous System Diseases (4) · Hypotension (4) · Movement Disorders (4) · Orthostatic Intolerance (4) · Synucleinopathies (4) · Vascular Diseases (4) · Neurodegenerative Diseases (3) · Parkinsonian Disorders (2) · Cerebellar Diseases (1)
Epinephrine (1) · Exercise (1) · Fructose (1) · Immunoglobulins, Intravenous (1) · Insulin (1) · Midodrine (1) · Morphine (1) · Naloxone (1) · ampreloxetine (1) · fipamezole (1)
Albert Einstein College of Medicine (1) · Beth Israel Deaconess Medical Center (1) · H. Lundbeck A/S (1) · Juvantia Pharma Ltd (1) · Theravance Biopharma (1) · Vanderbilt University Medical Center (1)
United States (5) · France (1) · Japan (1) · Portugal (1)
Italo Biaggioni, MD (1) · Luis E Okamoto, MD (1) · Meredith Hawkins, M.D., M.S. (1) · Olivier Rascol, MD (1) · Roy Freeman, MD (1)
PMID 22522612, PMID 28860128, PMID 33782836, PMID 34657222, PMID 42044642
R01DK079974 (1), R01HL144568 (1), U54NS065736 (1)